First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We write for you

It’s a public service and we refuse to erect a paywall and force you to pay for truth. Instead, we ask (nicely and often) that those of you who can afford to, become a Maverick Insider and help with whatever you can. In order for truth not to become a thing of the past, we need to keep going.

Currently, 18,000 (or less than 0.3%) of our brave and generous readers are members; which says a lot about their characters and commitment to our country. These people are paying for a free service in order to keep it free for everyone.

They are the true South AfriCANs.(Sorry, we couldn’t help ourselves.)

Support Daily Maverick→
Payment options

Moderna vaccine to be reviewed for WHO emergency listin...

Newsdeck

Newsdeck

Moderna vaccine to be reviewed for WHO emergency listing on April 30 – WHO spokesman

epa08931994 A vial of the first batch of Covid-19 vaccine by Moderna arrives in to the Movianto company in Oss, the Netherlands, 11 January 2020. It is the second vaccine after the BioNTech-Pfizer Covid-19 vaccine that has been approved in the EU. EPA-EFE/ROB ENGELAAR
By Reuters
26 Apr 2021 0

GENEVA, April 26 (Reuters) - Moderna's COVID-19 vaccine will be reviewed on April 30 by technical experts for possible WHO emergency-use listing, a World Health Organization spokesman told Reuters.

“We are discussing the Moderna COVID-19 vaccine on Friday…,” WHO spokesman Christian Lindmeier said in reply to a query. A decision on the U.S. drugmaker’s vaccine, now being evaluated under the abridged procedure on the basis of prior review by the European Medicines Agency, was expected in one to four days after that, Lindmeier said.

So far COVID-19 vaccines made by Pfizer, AstraZeneca and Johnson & Johnson have received WHO approval, which is a signal to national regulatory authorities on a product’s safety and efficacy.

The WHO committee of technical experts were on Monday reviewing the COVID-19 vaccine of Chinese drugmaker Sinopharm and is due to review the Sinovac product at its next meeting on May 3, according to the WHO.

Stephane Bancel, Moderna CEO, told an event last Friday that it was on track to make up to 1 billion doses of its COVID-19 vaccine this year and 1.4 billion next year.

“We’re in the final stretch to get an agreement with COVAX,” Bancel said, referring to the vaccine-sharing facility run by the GAVI Vaccine Alliance and WHO to bring doses to lower income countries. (Reporting by Stephanie Nebehay; editing by Emma Farge and Mark Heinrich)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]

Gallery

Please peer review 3 community comments before your comment can be posted